December 16, 2001
Neuroendocrinology Letters, Home
Vol. 22 No. 6 Preview
Contact us
Subscription info
Neuroendocrinology Letters incl. Psychoneuroimmunology & Chronobiology

including Psychoneuroimmunology, Neuro
Reproductive Medicine, Chronobiology
and Human Ethology
ISSN 0172–780X

NEL VOL. 22 No. 6

Original Article

Melatonin aggravates Ehrlich ascites development

2001; 22:432-434
pii: NEL220601A06


full text pdf (83kb)

Melatonin Shortens the Survival Rate of Ehrlich Ascites-inoculated Mice
by Sergiu-Bogdan Catrina, Elena Curca, Anca Irinel Catrina, Corina Radu & Mihai Coculescu

melatonin, malignancy, pineal low-molecular factor(s), Ehrlich ascites and survival rate

Submitted: November 1, 2001
Accepted: November 18, 2001


OBJECTIVES Pineal gland may have a role in organism’s protection against cancer. Melatonin as well as still unidentified low-weight molecular pineal substance(s) have been reported to have growth inhibitory effect on different tumor cells. We tested the influence of melatonin and of a bovine pineal extract on the survival rate of AKR mice inoculated with Ehrlich ascites. The tumor is known to have an accelerated development after pinealectomy.

MATERIAL AND METHODS: Male AKR mice, kept under a 14/10 hours - Light /Dark cycle, were inoculated intraperitoneally (i.p.) with 1.5x 106 Ehrlich ascites cells. On day three after inoculation the animals were divided in three groups (n=10). Each animal received i.p. daily (20.00H), until their death, 250 ml of solution containing melatonin (250 mg), pineal extract (equivalent of 1 bovine pineal gland) or saline.

RESULTS: The average survival rate of the animals treated with melatonin was shorter (14.8+/-2.23 days) compared to control animals (21.9+/-2.21 days) (p=0.01). The animals treated with the pineal extract had a longer survival rate (22.6 +/- 1.8 days) but not statistically significant. The pineal extract was not available for testing at higher doses.

CONCLUSION: In our model, melatonin had a deleterious effect on the survival rate raising the question whether it is correct to assume that the hormone shows lack of adverse reactions.


Copyright  Neuroendocrinology Letters 2001
All rights reserved. No part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or ortherwise, without prior written permission from the Editor-in-Chief.